The Canadian Pharma Pipeline — Finally Legible
I moved to Canada with a background in pharma and healthcare strategy — but like many immigrants, breaking back into the same field wasn’t immediate. So instead of losing touch, I started rebuilding my understanding from the ground up. I began with what I knew — the US system and FDA approvals — and mapped how those drugs actually move through Health Canada, CADTH, and into reimbursement. That became QuantiWise. Today, it tracks the Canadian pipeline end-to-end — and with QuantiCI, highlights what actually matters each week. No paywall. No noise. Just clarity. Reachout to [email protected] for the password.
when I started mapping this myself.
Each tool was built to solve a real problem — not to add features for the sake of it. If something's here, it's because I needed it.
Pipeline Dashboard
243 FDA novel drug approvals from 2021 to present — all tracked against their Canadian regulatory journey. Filter by status, therapeutic area, or approval year. Sortable table with pipeline progress dots, source links, and indication details.
Visualize — Analytics
The pipeline data turned into charts you can actually use. FDA-to-Canada approval gap by therapy area, pipeline status breakdown, cohort conversion rates by year, and a full therapy area × status matrix. AI-computed strategic signals tell you what the data means.
QuantiCI — AI Digest
Generate a weekly pharma competitive intelligence digest on demand. Filter by therapy area, signal type, and geography. QuantiCI searches live sources and surfaces only what matters — regulatory, reimbursement, pipeline, policy, hiring signals, all with a "so what" framing.
gap I lived in.
I came to Canada with years of pharma experience and hit a wall I didn't expect. The Canadian market access landscape — regulatory pathways, HTA, reimbursement timelines — wasn't something I could find in one place. And without an existing network, there was no one to just ask.
So I started mapping it myself. Drug by drug. Database by database. Press release by press release. QuantiWise grew out of that process — a real attempt to organize what I was learning into something I could actually use.
What started as a tracking spreadsheet is now a full platform. A pipeline dashboard. Visual analytics. An AI digest. All built in the open, shaped by real use, still a work in progress. If you find it useful or have ideas — I'd genuinely love to hear from you.
US vs Canada: Speed, Pricing & Availability
The US and Canada share the longest international border — but their pharmaceutical markets operate in completely different ways.
Care is Decentralizing. Are Clinics Ready?
Homes are becoming the new clinics. From wearables to ambient sensors, the most important health decisions are happening outside hospital walls.
Operational Challenges Holding Back Care-at-Home
Scaling Health-at-Home is not just about technology or staffing — it's about reconfiguring how care flows across people, systems, and data.
Eli Lilly + Nvidia: AI is Now Infrastructural in Pharma
LillyPod's strategic intent goes beyond scale — it's about escaping pharma's boom-and-bust cycle through AI-driven R&D.
Home Health: Canada's Most Underestimated Pillar
As hospitals face capacity strain and Canada's population ages, home health is becoming the pressure valve of the system.
Future-Ready Pharma: What Sets J&J, Roche & AZ Apart
IMD's 2025 Future Readiness Indicator shows blockbusters alone won't cut it. Platform thinking and AI integration separate the leaders.
Get notified when
new drugs are added
QuantiWise tracks all FDA novel drug approvals from 2021 to present — updated monthly as new drugs enter the Canadian pipeline. Drop your email and I'll let you know when the dashboard grows — no spam, just signal.
Start with the Pipeline Dashboard
243 FDA-approved drugs · Canadian regulatory status · 2021–2026 · updated monthly. Free, no login required.